Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 17;17(4):e82463.
doi: 10.7759/cureus.82463. eCollection 2025 Apr.

Lipid Dysregulation in Sebaceous Gland Disorders and the Impact of Sphingolipid Metabolism on Acne Pathogenesis

Affiliations
Review

Lipid Dysregulation in Sebaceous Gland Disorders and the Impact of Sphingolipid Metabolism on Acne Pathogenesis

Kaitlyn Miner et al. Cureus. .

Abstract

Lipid dysregulation within sebaceous glands is a critical factor underlying the pathogenesis of sebaceous gland disorders, particularly acne vulgaris. Sebaceous glands synthesize and secrete a complex mixture of lipids, including triglycerides, wax esters, free fatty acids, and sphingolipids, which contribute to skin barrier function and microbial homeostasis. Dysregulated lipid production, characterized by increased sebum secretion and altered lipid composition, has been implicated in promoting Cutibacterium acnes proliferation, hyperkeratinization, and inflammation, key processes in acne pathogenesis. Recent research highlights the pivotal role of sphingolipid metabolism, particularly ceramides, in modulating sebaceous gland activity and skin inflammation. Ceramide deficiencies in acne-prone skin contribute to compromised barrier integrity, increased microbial colonization, and an exaggerated inflammatory response. Furthermore, sphingolipid intermediates such as sphingosine-1-phosphate (S1P) influence sebocyte differentiation, lipid synthesis, and cytokine release, linking sphingolipid metabolism to sebaceous gland homeostasis. Emerging therapeutic strategies targeting sphingolipid pathways offer new opportunities for managing sebaceous gland disorders. Topical and systemic therapies designed to restore ceramide levels and modulate S1P signaling have shown promise in preclinical studies, with potential to reduce sebum production, enhance barrier function, and attenuate inflammation. Additionally, sphingolipid-targeted formulations combined with established treatments, such as retinoids and antimicrobial agents, may enhance therapeutic outcomes while minimizing side effects. The dysregulation of sebaceous lipid metabolism, particularly sphingolipid pathways, plays a central role in acne pathogenesis, and emerging insights into these mechanisms are shaping innovative strategies for the treatment and prevention of sebaceous gland disorders.

Keywords: acne management; acne vulgaris knowledge; lipid metabolism; sebaceous glands; skin inflammation.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Similar articles

Cited by

References

    1. Acne vulgaris: a review of the pathophysiology, treatment, and recent nanotechnology based advances. Vasam M, Korutla S, Bohara RA. Biochem Biophys Rep. 2023;36:101578. - PMC - PubMed
    1. Systematic review of the epidemiology of acne vulgaris. Heng AH, Chew FT. Sci Rep. 2020;10:5754. - PMC - PubMed
    1. A review of diagnosis and treatment of acne in adult female patients. Tan AU, Schlosser BJ, Paller AS. Int J Womens Dermatol. 2018;4:56–71. - PMC - PubMed
    1. Acne vulgaris. Aydemir EH. Turk Pediatri Ars. 2014;49:13–16. - PMC - PubMed
    1. Acne vulgaris. Williams HC, Dellavalle RP, Garner S. Lancet. 2012;379:361–372. - PubMed

LinkOut - more resources